Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 10:31:21 2024-05-20 EDT			5-day change	1st Jan Change
9.02 ^SEK	+0.22%		-1.96%	-2.38%

05-10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.

November 04, 2022 at 03:30 am

From July 25, 2022 to September 30, 2022, the company has repurchased 24,000 shares, representing 0.05% for SEK 0.18 million. With this, the company has completed the repurchase of 24,000 shares, representing 0.05% for SEK 0.18 million under the buyback announced on July 25, 2022.

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Initiator Pharma Issues New Shares for Debt Conversion	02-21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	01-08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	23-10-06	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	23-09-19	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	23-08-09	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	23-08-09	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	23-07-18	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	23-07-05	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	23-06-29	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	23-06-05	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	23-05-25	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	23-05-02	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	23-03-06	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	22-12-20	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	22-11-04	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	22-11-04	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	22-10-02	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	22-09-21	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-2.38%	44.48M
MODERNA, INC.	+38.24%	50.93B
IQVIA HOLDINGS INC.	-0.54%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.36%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-22.58%	18.9B
BIO-TECHNE CORPORATION	+8.32%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.58%	12.17B
MEDPACE HOLDINGS, INC.	+29.03%	12.16B

Other Biotechnology & Medical Research

Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.

Latest news about Initiator Pharma A/S

Chart Initiator Pharma A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research